{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T18:10:16Z","timestamp":1769537416569,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-061"],"award-info":[{"award-number":["2021-I2M-1-061"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-128"],"award-info":[{"award-number":["2022-PUMCH-B-128"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04259-x","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T04:56:00Z","timestamp":1769489760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Local-regional therapy plus ICIs, chemotherapy, and lenvatinib versus ICIs plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter study"],"prefix":"10.1007","volume":"75","author":[{"given":"Mingming","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanhua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shikang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zixiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingjian","family":"Piao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weixuan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiongyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongliang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"4259_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/s0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX (2021) Biliary tract cancer. Lancet 397:428\u2013444. https:\/\/doi.org\/10.1016\/s0140-6736(21)00153-7","journal-title":"Lancet"},{"key":"4259_CR2","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1007\/s12094-015-1436-2","volume":"17","author":"M Benavides","year":"2015","unstructured":"Benavides M, Ant\u00f3n A, Gallego J et al (2015) Biliary tract cancers: SEOM clinical guidelines. Clin Transl Oncol 17:982\u2013987. https:\/\/doi.org\/10.1007\/s12094-015-1436-2","journal-title":"Clin Transl Oncol"},{"key":"4259_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, Teh BT, Wongkham S, Gores GJ (2021) Cholangiocarcinoma. Nat Rev Dis Primers 7:65. https:\/\/doi.org\/10.1038\/s41572-021-00300-2","journal-title":"Nat Rev Dis Primers"},{"key":"4259_CR4","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","volume":"21","author":"SK Saha","year":"2016","unstructured":"Saha SK, Zhu AX, Fuchs CS, Brooks GA (2016) Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist 21:594\u2013599. https:\/\/doi.org\/10.1634\/theoncologist.2015-0446","journal-title":"Oncologist"},{"key":"4259_CR5","doi-asserted-by":"publisher","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","volume":"27","author":"JW Valle","year":"2016","unstructured":"Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D (2016) Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:v28\u2013v37. https:\/\/doi.org\/10.1093\/annonc\/mdw324","journal-title":"Ann Oncol"},{"key":"4259_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","volume":"13","author":"JM Banales","year":"2016","unstructured":"Banales JM, Cardinale V, Carpino G et al (2016) Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 13:261\u2013280. https:\/\/doi.org\/10.1038\/nrgastro.2016.51","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4259_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"key":"4259_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"4259_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/1073274817729241","volume":"24","author":"YS Chun","year":"2017","unstructured":"Chun YS, Javle M (2017) Systemic and adjuvant therapies for intrahepatic cholangiocarcinoma. Cancer Control 24:1073274817729241. https:\/\/doi.org\/10.1177\/1073274817729241","journal-title":"Cancer Control"},{"key":"4259_CR10","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1158\/2159-8290.Cd-17-0245","volume":"7","author":"JW Valle","year":"2017","unstructured":"Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX (2017) New horizons for precision medicine in biliary tract cancers. Cancer Discov 7:943\u2013962. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-0245","journal-title":"Cancer Discov"},{"key":"4259_CR11","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/cncr.29692","volume":"122","author":"NF Esnaola","year":"2016","unstructured":"Esnaola NF, Meyer JE, Karachristos A, Maranki JL, Camp ER, Denlinger CS (2016) Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer 122:1349\u20131369. https:\/\/doi.org\/10.1002\/cncr.29692","journal-title":"Cancer"},{"key":"4259_CR12","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273\u20131281. https:\/\/doi.org\/10.1056\/NEJMoa0908721","journal-title":"N Engl J Med"},{"key":"4259_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"T Okusaka","year":"2010","unstructured":"Okusaka T, Nakachi K, Fukutomi A et al (2010) Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 103:469\u2013474. https:\/\/doi.org\/10.1038\/sj.bjc.6605779","journal-title":"Br J Cancer"},{"key":"4259_CR14","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/jco.21.01944","volume":"40","author":"CH Lee","year":"2022","unstructured":"Lee CH, Voss MH, Carlo MI et al (2022) Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates. J Clin Oncol 40:2333\u20132341. https:\/\/doi.org\/10.1200\/jco.21.01944","journal-title":"J Clin Oncol"},{"key":"4259_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/s1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH et al (2022) Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23:234\u2013247. https:\/\/doi.org\/10.1016\/s1470-2045(21)00692-6","journal-title":"Lancet Oncol"},{"key":"4259_CR16","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1200\/jco.19.03296","volume":"38","author":"S Fukuoka","year":"2020","unstructured":"Fukuoka S, Hara H, Takahashi N et al (2020) Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol 38:2053\u20132061. https:\/\/doi.org\/10.1200\/jco.19.03296","journal-title":"J Clin Oncol"},{"key":"4259_CR17","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/s0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401:1853\u20131865. https:\/\/doi.org\/10.1016\/s0140-6736(23)00727-4","journal-title":"Lancet"},{"key":"4259_CR18","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jhep.2025.05.003","volume":"83","author":"DY Oh","year":"2025","unstructured":"Oh DY, He AR, Qin S et al (2025) Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study. J Hepatol 83:1092\u20131101. https:\/\/doi.org\/10.1016\/j.jhep.2025.05.003","journal-title":"J Hepatol"},{"key":"4259_CR19","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S et al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 1:EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015","journal-title":"NEJM Evid"},{"key":"4259_CR20","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/sj.bjc.6604129","volume":"98","author":"D Yoshikawa","year":"2008","unstructured":"Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, Hirohashi S, Shibata T (2008) Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 98:418\u2013425. https:\/\/doi.org\/10.1038\/sj.bjc.6604129","journal-title":"Br J Cancer"},{"key":"4259_CR21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","volume":"8","author":"GM Shi","year":"2023","unstructured":"Shi GM, Huang XY, Wu D et al (2023) Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study. Signal Transduct Target Ther 8:106. https:\/\/doi.org\/10.1038\/s41392-023-01317-7","journal-title":"Signal Transduct Target Ther"},{"key":"4259_CR22","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1007\/s00262-023-03466-8","volume":"72","author":"C Zhu","year":"2023","unstructured":"Zhu C, Li H, Yang X et al (2023) Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study. Cancer Immunol Immunother 72:2949\u20132960. https:\/\/doi.org\/10.1007\/s00262-023-03466-8","journal-title":"Cancer Immunol Immunother"},{"key":"4259_CR23","doi-asserted-by":"publisher","first-page":"1109292","DOI":"10.3389\/fimmu.2023.1109292","volume":"14","author":"C Zhu","year":"2023","unstructured":"Zhu C, Xue J, Wang Y et al (2023) Efficacy and safety of lenvatinib combined with PD-1\/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer. Front Immunol 14:1109292. https:\/\/doi.org\/10.3389\/fimmu.2023.1109292","journal-title":"Front Immunol"},{"key":"4259_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111642","volume":"129","author":"T Zhang","year":"2024","unstructured":"Zhang T, Zhu C, Zhang N et al (2024) Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer. Int Immunopharmacol 129:111642. https:\/\/doi.org\/10.1016\/j.intimp.2024.111642","journal-title":"Int Immunopharmacol"},{"key":"4259_CR25","first-page":"1026","volume":"13","author":"Y Wang","year":"2023","unstructured":"Wang Y, Xun Z, Yang X et al (2023) Local-regional therapy combined with toripalimab and lenvatinib in patients with advanced biliary tract cancer. Am J Cancer Res 13:1026\u20131037","journal-title":"Am J Cancer Res"},{"key":"4259_CR26","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s00262-023-03399-2","volume":"72","author":"Y Wang","year":"2023","unstructured":"Wang Y, Yang X, Wang Y et al (2023) Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study. Cancer Immunol Immunother 72:2197\u20132204. https:\/\/doi.org\/10.1007\/s00262-023-03399-2","journal-title":"Cancer Immunol Immunother"},{"key":"4259_CR27","doi-asserted-by":"publisher","first-page":"1084843","DOI":"10.3389\/fimmu.2023.1084843","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang Y, Zhang N, Xue J et al (2023) Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC. Front Immunol 14:1084843. https:\/\/doi.org\/10.3389\/fimmu.2023.1084843","journal-title":"Front Immunol"},{"key":"4259_CR28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00262-025-04085-1","volume":"74","author":"S Li","year":"2025","unstructured":"Li S, Yu G, Wang M et al (2025) Efficacy and safety of local-regional therapy combined with chemotherapy, immune checkpoint inhibitors and lenvatinib as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study. Cancer Immunol Immunother 74:229. https:\/\/doi.org\/10.1007\/s00262-025-04085-1","journal-title":"Cancer Immunol Immunother"},{"key":"4259_CR29","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Seymour L, Liti\u00e8re S et al (2016) RECIST 1.1 - standardisation and disease-specific adaptations: perspectives from the RECIST working group. Eur J Cancer 62:138\u2013145. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.082","journal-title":"Eur J Cancer"},{"key":"4259_CR30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 112:90\u201392. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"4259_CR31","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","volume":"14","author":"S Zhu","year":"2021","unstructured":"Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, Li Z, Pan CX (2021) Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol 14:156. https:\/\/doi.org\/10.1186\/s13045-021-01164-5","journal-title":"J Hematol Oncol"},{"key":"4259_CR32","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","volume":"28","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, Zitvogel L, Kroemer G (2015) Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28:690\u2013714. https:\/\/doi.org\/10.1016\/j.ccell.2015.10.012","journal-title":"Cancer Cell"},{"key":"4259_CR33","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ijc.26094","volume":"130","author":"AC Ziogas","year":"2012","unstructured":"Ziogas AC, Gavalas NG, Tsiatas M et al (2012) VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor type 2. Int J Cancer 130:857\u2013864. https:\/\/doi.org\/10.1002\/ijc.26094","journal-title":"Int J Cancer"},{"key":"4259_CR34","doi-asserted-by":"publisher","first-page":"545","DOI":"10.4049\/jimmunol.0900397","volume":"184","author":"A Basu","year":"2010","unstructured":"Basu A, Hoerning A, Datta D, Edelbauer M, Stack MP, Calzadilla K, Pal S, Briscoe DM (2010) Cutting edge: Vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production. J Immunol 184:545\u2013549. https:\/\/doi.org\/10.4049\/jimmunol.0900397","journal-title":"J Immunol"},{"key":"4259_CR35","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/1751-2980.13127","volume":"23","author":"N Zhang","year":"2022","unstructured":"Zhang N, Yu BR, Wang YX et al (2022) Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma. J Dig Dis 23:535\u2013545. https:\/\/doi.org\/10.1111\/1751-2980.13127","journal-title":"J Dig Dis"},{"key":"4259_CR36","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/15384047.2020.1834792","volume":"22","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Chen Y, Du S, Yang X, Chen Y, Ji Y, Zeng Z (2021) Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases. Cancer Biol Ther 22:175\u2013183. https:\/\/doi.org\/10.1080\/15384047.2020.1834792","journal-title":"Cancer Biol Ther"},{"key":"4259_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0692-z","volume":"7","author":"X Liu","year":"2019","unstructured":"Liu X, Yao J, Song L, Zhang S, Huang T, Li Y (2019) Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade. J Immunother Cancer 7:204. https:\/\/doi.org\/10.1186\/s40425-019-0692-z","journal-title":"J Immunother Cancer"},{"key":"4259_CR38","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20230079","volume":"96","author":"Z Ning","year":"2023","unstructured":"Ning Z, Xie L, Yan X, Hua Y, Shi W, Lin J, Xu L, Meng Z (2023) Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study. Br J Radiol 96:20230079. https:\/\/doi.org\/10.1259\/bjr.20230079","journal-title":"Br J Radiol"},{"key":"4259_CR39","doi-asserted-by":"publisher","first-page":"1397827","DOI":"10.3389\/fimmu.2024.1397827","volume":"15","author":"R Zhao","year":"2024","unstructured":"Zhao R, Zhou J, Miao Z, Xiong X, Wei W, Li S, Guo R (2024) Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma. Front Immunol 15:1397827. https:\/\/doi.org\/10.3389\/fimmu.2024.1397827","journal-title":"Front Immunol"},{"key":"4259_CR40","doi-asserted-by":"publisher","first-page":"e352","DOI":"10.1016\/s1470-2045(24)00075-5","volume":"25","author":"C Lynch","year":"2024","unstructured":"Lynch C, Pitroda SP, Weichselbaum RR (2024) Radiotherapy, immunity, and immune checkpoint inhibitors. Lancet Oncol 25:e352\u2013e362. https:\/\/doi.org\/10.1016\/s1470-2045(24)00075-5","journal-title":"Lancet Oncol"},{"key":"4259_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242316691","author":"SH Jeon","year":"2023","unstructured":"Jeon SH, Song C, Eom KY, Kim IA, Kim JS (2023) Modulation of CD8(+) T cell responses by radiotherapy-current evidence and rationale for combination with immune checkpoint inhibitors. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms242316691","journal-title":"Int J Mol Sci"},{"key":"4259_CR42","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1172\/jci43656","volume":"121","author":"WJ Lesterhuis","year":"2011","unstructured":"Lesterhuis WJ, Punt CJ, Hato SV et al (2011) Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest 121:3100\u20133108. https:\/\/doi.org\/10.1172\/jci43656","journal-title":"J Clin Invest"},{"key":"4259_CR43","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s13402-020-00552-2","volume":"43","author":"H Zhu","year":"2020","unstructured":"Zhu H, Shan Y, Ge K, Lu J, Kong W, Jia C (2020) Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy. Cell Oncol (Dordr) 43:1203\u20131214. https:\/\/doi.org\/10.1007\/s13402-020-00552-2","journal-title":"Cell Oncol (Dordr)"},{"key":"4259_CR44","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.2147\/cmar.S188316","volume":"11","author":"M Capozzi","year":"2019","unstructured":"Capozzi M, De Divitiis C, Ottaiano A, von Arx C, Scala S, Tatangelo F, Delrio P, Tafuto S (2019) Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment. Cancer Manag Res 11:3847\u20133860. https:\/\/doi.org\/10.2147\/cmar.S188316","journal-title":"Cancer Manag Res"},{"key":"4259_CR45","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.4251\/wjgo.v16.i7.3256","volume":"16","author":"Y Guo","year":"2024","unstructured":"Guo Y, Li RC, Xia WL, Yang X, Zhu WB, Li FT, Hu HT, Li HL (2024) Immune effect and prognosis of transcatheter arterial chemoembolization and tyrosine kinase inhibitors therapy in patients with hepatocellular carcinoma. World J Gastrointest Oncol 16:3256\u20133269. https:\/\/doi.org\/10.4251\/wjgo.v16.i7.3256","journal-title":"World J Gastrointest Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04259-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04259-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04259-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T04:56:01Z","timestamp":1769489761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04259-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["4259"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04259-x","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study adhered to the Declaration of Helsinki and received ethical approvals from ethics committees of PUMCH, NCC, PLAGH, and CJFH (No. I-24PJ2728; No. I-25PJ0158; No. 25\/138-5084; No. KY-2025-1-18-1; No. 2025-KY-143), with informed consent waived owing to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"36"}}